Abstract
A dedicated bifurcation stent has the potential to simplify and improve the outcomes of percutaneous coronary bifurcation intervention. We report a patient from the first human use trial of a novel paclitaxel-eluting dedicated bifurcation stent. By 6 months, there were no adverse events and the stent lumen and, in particular, the side-branch ostium were widely patent on angiography and intravascular ultrasound. This device may offer superior results without the limitations of conventional stent techniques in the treatment of coronary bifurcation disease.
| Original language | English |
|---|---|
| Pages (from-to) | 637-40 |
| Number of pages | 4 |
| Journal | Catheterization and Cardiovascular Interventions |
| Volume | 73 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Apr 2009 |
Bibliographical note
Copyright 2009 Wiley-Liss, Inc.Keywords
- Angioplasty, Balloon, Coronary/adverse effects
- Cardiovascular Agents/administration & dosage
- Clinical Trials as Topic
- Coronary Angiography
- Coronary Artery Disease/pathology
- Drug-Eluting Stents
- Humans
- Male
- Middle Aged
- Paclitaxel/administration & dosage
- Prosthesis Design
- Severity of Illness Index
- Treatment Outcome
- Ultrasonography, Interventional
